Vedolizumab Quantitation with Antibodies
Order Code:
VEDOZ
Test Summary
Assessing for primary or secondary loss of response to therapy with vedolizumab. An aid to achieving desired serum concentrations of vedolizumab.
Aliases
- Entyvio
Specimen Collection
Special Instructions
N/A
Preferred Specimen
1.5 mL serum from a red top tube
Minimum Volume
0.75 mL serum
Instructions
1. Draw blood immediately before next scheduled dose (trough specimen).
2. Centrifuge within 2 hours of draw.
3. Transfer serum to a pour off tube.
2. Centrifuge within 2 hours of draw.
3. Transfer serum to a pour off tube.
Patient Preparation
1. For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
2. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to testing for vedolizumab quantitation in serum.
2. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to testing for vedolizumab quantitation in serum.
Storage
Plastic screw-cap vial
Transport Temperature
Refrigerated
Specimen Stability
- Room Temperature: N/A
- Refrigerated: 28 days
- Frozen = 28 days
Limitations
N/A
Other Acceptable Specimens
Serum from a serum separator tube
Unacceptable Specimens
N/A
Order Code
VEDOZ
EPIC (Premier) Code
LAB6765
Includes
N/A
CPT Code
- 80280
- 82397
Billing Code
- 650057
- 650058
CPT Statement
Methodology
Liquid Chromatography- Mass Spectrometry (LC-MS/MS),
Electrochemiluminescent Bridging Immunoassay
Electrochemiluminescent Bridging Immunoassay
FDA Status
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
Physician Attestation of Informed Consent
N/A
Testing Laboratory
Mayo Clinic Laboratories -- Rochester Superior Drive
3050 Superior Drive NW
Rochester MN, 55901
3050 Superior Drive NW
Rochester MN, 55901
Department
Reference Testing
Reference Range
N/A
Setup Schedule / Expected Turnaround Time
Vedolizumab Quantitation: Monday, Wednesday, Thursday/Vedolizumab Antibodies: Tuesday, Friday; Report available: 5 - 8 days
Specimen Collection
Special Instructions
N/A
Preferred Specimen
1.5 mL serum from a red top tube
Minimum Volume
0.75 mL serum
Instructions
1. Draw blood immediately before next scheduled dose (trough specimen).
2. Centrifuge within 2 hours of draw.
3. Transfer serum to a pour off tube.
2. Centrifuge within 2 hours of draw.
3. Transfer serum to a pour off tube.
Patient Preparation
1. For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
2. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to testing for vedolizumab quantitation in serum.
2. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to testing for vedolizumab quantitation in serum.
Storage
Plastic screw-cap vial
Transport Temperature
Refrigerated
Specimen Stability
- Room Temperature: N/A
- Refrigerated: 28 days
- Frozen = 28 days
Limitations
N/A
Other Acceptable Specimens
Serum from a serum separator tube
Unacceptable Specimens
N/A
Result Information
Methodology
Liquid Chromatography- Mass Spectrometry (LC-MS/MS),
Electrochemiluminescent Bridging Immunoassay
Electrochemiluminescent Bridging Immunoassay
Testing Laboratory
N/A
Reference Range
N/A
Setup Schedule / Expected Turnaround Time
Vedolizumab Quantitation: Monday, Wednesday, Thursday/Vedolizumab Antibodies: Tuesday, Friday; Report available: 5 - 8 days